

March 17, 2021

Todd C. Brady, M.D., Ph.D.
Chief Executive Officer
Aldeyra Therapeutics, Inc.
131 Hartwell Avenue, Suite 320
Lexington, MA 02421

Therapeutics, Inc.

Statement on Form S-3
2021

Re: Aldeyra

Registration

Filed March 11,

File No. 333-254175

Dear Dr. Brady:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sarmento at 202-551-3798 with any questions.

Please contact Ada D.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Keith J. Scherer, Esq.